Investing

Theravance Biopharma : TBPH

TBPH

Stock Data

$20.74

$0.37 (1.82%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Theravance Biopharma is a biopharmaceutical company focused on developing respiratory medicines primarily for the US and European markets. Its flagship product, YUPELRI, is a once-daily treatment for chronic obstructive pulmonary disease (COPD). The company is also working on Ampreloxetine for neurogenic orthostatic hypotension and TRELEGY for COPD and asthma. Founded in 2013 and headquartered in South San Francisco, California, Theravance Biopharma has partnerships with Pfizer and Viatris for advancing its research and development efforts.

All Theravance Biopharma Articles

2 Articles

Rich Duprey | Sep 29, 2024 at 11:32 AM EDT

Invest Alongside Wall Street Legend Seth Klarman: 2 New Stocks He Bought and 1 He Dumped

Enigmatic investing legend Seth Klarman runs the Boston-based Baupost Group hedge fund that has around $27 billion in assets under…

Chris Lange | Aug 25, 2021 at 8:22 AM EDT

Wednesday’s Top Analyst Upgrades and Downgrades: Beyond Meat, Boston Beer, Campbell Soup, Nordstrom, Okta, Owens Corning and Victoria’s Secret

Wednesday's top analyst upgrades and downgrades included Beyond Meat, Boston Beer, Campbell Soup, Nordstrom, Okta, Owens Corning and Victoria’s Secret.